Quantcast

Latest Amgen Stories

2014-10-21 16:28:24

THOUSAND OAKS, Calif., Oct. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen maintains an active, engaged dialogue with all shareholders. Amgen has always appreciated the perspectives of all of its shareholders, including Third Point, and welcomes constructive input toward our common goal of enhancing shareholder value. Amgen's Board of Directors frequently...

2014-10-17 23:02:58

RnRMarketResearch.com adds “Osteoporosis & Osteoarthritis – Pipeline Review, H2 2014” to its store. The report provides an overview of the Osteoporosis’s and Osteoarthritis’s therapeutic pipeline. Dallas, Texas (PRWEB) October 17, 2014 This report provides comprehensive information on the therapeutic development for Osteoarthritis & Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route...

2014-10-17 23:02:09

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled persons may be using Enbrel that, based on the manufacturer’s own guidelines, should not be used and should be discarded immediately; the plaintiff further alleges that the unapproved Enbrel is ineffective in treating his arthritis...

2014-10-17 16:24:55

THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor. "We are pleased to welcome Dr. Sandy Williams to the Amgen Board," said Robert A. Bradway, chairman and chief executive officer of Amgen. "Dr. Williams' deep and distinguished experience in academic medicine and his direct experience in our...

2014-10-17 16:24:49

THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend will be paid on Dec. 5, 2014, to all stockholders of record as of the close of business on Nov. 13, 2014. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering...

2014-10-17 08:26:00

Amgen Seeks Injunction Related to PCSK9 Inhibitor THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron") for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which...

2014-10-14 08:31:25

DUBLIN, Oct. 14 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic...

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is for the...

2014-10-08 08:28:04

Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Oct. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira(®) (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint. The primary endpoint was the Psoriasis Area and Severity Index (PASI) percent improvement from baseline to week 16 of treatment. At week 16,...

2014-10-07 12:30:55

CRANBURY, N.J., Oct. 7, 2014 /PRNewswire/ -- Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors. http://photos.prnewswire.com/prnvar/20141006/150533 Pankaj Mohan, Ph.D., Founder and CEO of Oncobiologics, stated, "We are delighted to welcome Dr. Brady to our Board. Given his experience as a venture capital investor,...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.